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hazard of death for treatment C. If the 
ratio of hazards r(t)=λ
e
(t)/λ
c
(t) does not 
depend on time t then the proportional 
hazards assumption holds. Denoting 
this ratio by HR we can interpret HR 
= 0.75 (without reference to time) as 
“patients on treatment E have a 25% 
reduced risk of death relative to treat-
ment C.” If we switch the interpretation 
to be in terms of C relative to E then this 
is λ
c
(t)/λ
e
(t)=1/HR, which means that 
the hazard for C is (1/0.75) or 133% 
the hazard of E. Note that [λ
c
(t)–λ
e
(t)]/
λ
e
(t)=1/HR − 1, where λ
c
(t)–λ
e
(t) repre-
sents how much treatment C increases 
the hazard of death compared with E. 
Then 1/HR − 1 = 33% is the percentage 
increase in the hazard of death for treat-
ment C relative to treatment E.
Because survival probabilities 
(OS curves) are an explicit mathematical 
expression of the hazard function, that 
“treatment E reduces the risk (hazard) 
of death” already directly translates into 
prolonged OS for E relative to C. As we 
design trials to assess whether an experi-
mental regimen prolongs OS relative to a 
control, the interpretation given by 1 − HR 
(E versus C) is what is needed.
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conduct a large prospective study (cur-
rently ongoing in our institution).
Finally, we once again thank Dr. 
Ismaili for his thoughtful comments and 
we are grateful to get the opportunity to 
clarify some points from our work. 
Ibrahim Elghissassi, MD 
Hassan Errihani, MD
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In Response:
appropriate and is standard throughout 
the statistical and medical literature. The 
interpretation provided by (2), however, 
is not sound and can cause considerable 
miscommunication of study results. 
Statement (2) suggests that treatment 
E extends the survival times of patients 
after treatment E by 33% compared with 
the survival times of patients after treat-
ment C. For example, 1-year OS under 
treatment C is extended to 1.33 years 
under treatment E, 2-year OS extended 
to 2.66 years, and so on. The degree of 
improvement in OS times or probabili-
ties cannot by itself be summarized by a 
single value as survival differences will 
vary across time. Although the HR is 
generally considered the most important 
comprehensive summary of survival 
comparisons, its interpretation should 
not be taken out of context.
The authors’ interpretation 
assumes that survival times follow an 
exponential distribution. In this case, 
when both treatment groups follow expo-
nential distributions, then the ratio of 
medians, m
e
/m
c
 (say), is equal to 1/HR. 
The exponential model, however, should 
not be the basis for general interpreta-
tion. For example, suppose that treat-
ment C survival times follow a Weibull 
model with shape parameter ν and scale 
parameter θ (cf. ref.2), and that the hazard 
function for treatment E is equal to three-
fourths the hazard function for treatment 
C. We note that the exponential model is 
a special case of the Weibull model with 
shape parameter ν=1. Then HR=0.75 
and the ratio of medians is equal to 1/
HR=1.33 if and only if ν=1. However, 
if ν=0.25, for example, then the ratio of 
medians is equal to 3.16, and if ν=4, then 
the ratio is 1.07. These examples illus-
trate the pitfalls of interpreting 1/HR as 
the “increase in survival time.”
Here we clarify that for HR=0.75, 
1 − HR = 0.25 means that “treatment E 
reduces the risk of death by 25% rela-
tive to treatment C,” whereas 1/HR − 1 = 
0.33 means that “treatment C increases 
the risk of death by 33% relative to 
treatment E.” In other words, convert-
ing the interpretation from 1 − HR to 
1/HR − 1 simply changes the reference 
group; from E versus C to C versus E. 
This can be seen from the definition 
of the HR. Let λ
e
 denote the hazard of 
death for treatment E, and λ
c
 denote the 
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In their article, Barraclough et 
al.1 provide important insights into 
the interpretation of hazard ratio 
(HR) estimates from Cox models and 
Kaplan–Meier curves from clinical tri-
als. Unfortunately, the authors provide 
a particular interpretation of the HR, 
which can distort both statistical and 
clinical interpretations. Specifically, 
the authors interpret (see ref.,1 p. 981, 
Box 2) a 0.75 HR for overall survival 
(OS), comparing treatment E (experi-
mental) versus C (control), as either (1) 
a 25% lower risk of death (via 100 × 
(1 − HR)%, denoted 1 − HR), or (2) a 
33% increase in the survival time (via 
100 × (1/HR − 1)%, denoted 1/HR − 1). 
The interpretation provided by (1) is 
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We appreciate the opportunity 
to reply to the letter by Leon et al. 
in response to our article on Hazard 
